Complete reference — mechanism, evidence summary, dosing protocol, reconstitution guide, and COA-verified vendor pricing.
The CJC/Ipa combination works by simultaneously activating two independent GH-stimulating pathways in the pituitary gland — producing a synergistic GH pulse larger than either compound alone achieves.
CJC-1295 is a stabilized analog of the body's own Growth Hormone Releasing Hormone (GHRH). It binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating adenylyl cyclase and increasing intracellular cAMP. This triggers the synthesis and release of stored GH. The no-DAC version's short half-life (~30 minutes) means it produces a sharp, physiological-pattern GH pulse rather than sustained elevation.
Ipamorelin activates the GHS-R1a receptor (ghrelin receptor) — a completely separate receptor from the one CJC-1295 targets. GHS-R1a activation triggers intracellular calcium release in pituitary somatotrophs, directly driving GH secretion. Ipamorelin's high selectivity for GHS-R1a (vs older GHRPs like GHRP-6 which also hit ACTH and prolactin receptors) is why it lacks the cortisol and hunger side effects of its predecessors.
When both peptides are administered simultaneously, the pituitary receives two independent, complementary stimulatory signals. Research has demonstrated this combination produces GH pulses substantially larger than either compound alone — the effect is additive at minimum and potentially synergistic. Both pathways converge on GH release through different intracellular mechanisms, and simultaneous activation amplifies the output.
Key advantage over direct HGH: The CJC/Ipa stack works within the body's natural feedback loop. The hypothalamic-pituitary axis still regulates the response — somatostatin (the GH inhibitor) can still buffer excessive GH production. Direct HGH bypasses this regulation entirely, which is why the side-effect profiles differ significantly.
CJC-1295 and Ipamorelin each have their own research history — the combination stack itself has less direct clinical trial data, but the mechanistic rationale is well-supported.
| Compound | Study Type | Key Finding | Evidence Level |
|---|---|---|---|
| CJC-1295 (no DAC) | Human phase 1/2 | Dose-dependent GH and IGF-1 elevation in healthy adults; pulsatile pattern maintained | Human clinical data |
| Ipamorelin | Human phase 2 (postop ileus) | Evaluated for GI motility; also showed significant GH release in healthy subjects | Human clinical data |
| GHRH + GHRP combo | Human studies (general) | Combination consistently produces larger GH pulses than either alone; additive-synergistic effect documented | Combination studies |
| GH secretagogues (general) | Multiple human RCTs | Body composition improvements, improved sleep architecture, collagen synthesis in GH-deficient and aging populations | Moderate — population dependent |
Evidence context: CJC-1295 and Ipamorelin individually have human clinical data — that's more than many peptides in this space. The specific combination has less direct RCT data, but the synergistic GHRH+GHRP effect is well-documented in the research literature. Effect expectations are well-grounded mechanistically; individual variation is significant.
| Parameter | Value | Notes |
|---|---|---|
| Dose per peptide | 100–200 mcg each | CJC-1295 and Ipamorelin dosed equally; start at 100 mcg to assess tolerance |
| Frequency | 1–3x daily | Once daily (bedtime) most common; some add morning fasted dose |
| Timing | Fasted — 2+ hrs post-meal | Insulin blunts GH pulse; strict fasting around injection significantly improves response |
| Injection route | Subcutaneous | Abdomen, thigh, or deltoid; rotate sites |
| Cycle length | 8–16 weeks | Longer cycles risk receptor desensitization; break recommended |
| Break period | 4–8 weeks off | Allows pituitary sensitivity to normalize |
Before sleep (primary): The body's largest natural GH pulse occurs during the first hours of deep sleep. Injecting 30 minutes before sleep amplifies this pulse. This is the most common and well-supported timing in research protocols.
Morning fasted (secondary): Adding a second dose upon waking — before eating — captures another pulse window. Blood glucose must be stable and low for this to be effective.
Post-workout (advanced): Some protocols add a third injection 30–60 minutes after training when the GH axis is already primed. Requires strict fasting around the injection window.
CJC-1295 and Ipamorelin arrive as lyophilized (freeze-dried) powder and must be reconstituted before use.
Pre-blended vials: The 5mg/5mg blended vials (CJC-1295 + Ipamorelin combined) simplify dosing — reconstitute once and each draw contains both peptides in equal ratio. This is the most common format available from research vendors.
The CJC/Ipa combination is considered one of the cleaner GH protocols in the research space, largely because of Ipamorelin's selectivity profile.
GHRP-6 and GHRP-2 — the predecessors to Ipamorelin — significantly elevated cortisol and prolactin due to lower receptor selectivity. Ipamorelin was specifically developed to address this. Research consistently shows Ipamorelin produces GH release with minimal cortisol or prolactin elevation — a major advantage for longer research cycles.
All content is for educational and research purposes only. CJC-1295 and Ipamorelin are not approved for human therapeutic use. This is not medical advice. Consult a qualified healthcare provider.
All vendors below carry third-party Certificates of Analysis. Use promo codes at checkout for discounts.
Use the Dosage Calculator to calculate exact draw volumes based on your reconstitution concentration and target dose.
Start with the beginner's guide for a plain-English breakdown before diving into protocol specifics.
Read the 101 Guide → CJC/Ipa vs HGH →